Multidisciplinary Search

Multidisciplinary

Multidisciplinary

Home News Diseases Conferences Special Reports Multimedia

Lower joint replacement risk yet another benefit of statins

06 Jul 2020

Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.

Migraine a risk factor for dementia?

Pearl Toh, 29 Jun 2020

Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.

SELECT-PsA-1 demos upadacitinib benefits in psoriatic arthritis

Roshini Claire Anthony, 5 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Product Highlight - Crestor

26 Jun 2020

Crestor now can be prescribed for patients with severe renal impairment¹

The usual dose range applies in patients with mild to moderate renal impairment.
For patients with severe renal impairment not on haemodialysis, dosing of Crestor should be started at 5 mg once daily and not exceed 10 mg.

Crestor improves cardiovascular outcomes in patients with chronic kidney disease.²

Among moderate CKD patients, rosuvastatin was associated with a 45% reduction in first cardiovascular events (myocardial infarction, stroke, hospital stay for unstable angina, arterial revascularisation, or confirmed cardiovascular death.

References:
1. Crestor Malaysia Package Insert, 2019
2. Ridker PM, et al. J Am Coll Cardiol. 2010:55(12):1266-1273